ASCO 2014: Amgen's T-VEC shows efficacy, but is it enough?
This article was originally published in Scrip
Amgen's talimogene laherparepvec (T-VEC) for melanoma improved survival by 4.4 months in a Phase III monotherapy clinical trial and generated strong response rates in combination with the Bristol-Myers Squibb therapy Yervoy (ipilimumab) in an early-stage trial, but the cancer vaccine's market could be limited, according to analysts.
You may also be interested in...
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.
Biopharma companies struggle with which trials, if any, to pause or delay. Lilly said it wants to ease the burden on health care facilities, while Galapagos said its choice is related to patient safety.